Compare LMAT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | TMDX |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2006 | 2019 |
| Metric | LMAT | TMDX |
|---|---|---|
| Price | $95.59 | $72.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $105.80 | ★ $148.22 |
| AVG Volume (30 Days) | 303.1K | ★ 969.8K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | 30.57 | ★ 382.18 |
| EPS | ★ 0.68 | 0.20 |
| Revenue | $249,602,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $14.21 | $24.25 |
| Revenue Next Year | $8.88 | $18.75 |
| P/E Ratio | ★ $143.37 | $355.65 |
| Revenue Growth | 13.53 | ★ 37.13 |
| 52 Week Low | $79.01 | $60.11 |
| 52 Week High | $118.01 | $156.00 |
| Indicator | LMAT | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 47.33 |
| Support Level | $95.47 | $64.87 |
| Resistance Level | $97.83 | $79.60 |
| Average True Range (ATR) | 3.46 | 3.13 |
| MACD | -0.58 | 0.02 |
| Stochastic Oscillator | 2.30 | 34.57 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.